These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24662842)

  • 1. Lubiprostone (Amitiza) for opioid-induced constipation.
    Med Lett Drugs Ther; 2013 Jun; 55(1418):47-8. PubMed ID: 24662842
    [No Abstract]   [Full Text] [Related]  

  • 2. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract]   [Full Text] [Related]  

  • 3. Lubiprostone (amitiza) for chronic constipation.
    Med Lett Drugs Ther; 2006 Jun; 48(1236):47-8. PubMed ID: 16770297
    [No Abstract]   [Full Text] [Related]  

  • 4. Lubiprostone for chronic constipation in adults.
    Drug Ther Bull; 2014 Apr; 52(4):42-4. PubMed ID: 24722574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
    Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J
    World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
    Jamal MM; Adams AB; Jansen JP; Webster LR
    Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
    Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
    Drossman DA; Chey WD; Johanson JF; Fass R; Scott C; Panas R; Ueno R
    Aliment Pharmacol Ther; 2009 Feb; 29(3):329-41. PubMed ID: 19006537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lubiprostone for the treatment of opioid-induced bowel dysfunction.
    Wong BS; Camilleri M
    Expert Opin Pharmacother; 2011 Apr; 12(6):983-90. PubMed ID: 21385112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging new therapeutic options for the management of opioid induced constipation.
    Kapoor S
    J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):98-9. PubMed ID: 20345211
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapies for constipation.
    Thayalasekeran S; Ali H; Tsai HH
    World J Gastroenterol; 2013 Dec; 19(45):8247-51. PubMed ID: 24363515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE; Chey WD
    Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future therapies for chronic constipation.
    Tack J
    Best Pract Res Clin Gastroenterol; 2011 Feb; 25(1):151-8. PubMed ID: 21382586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
    Johanson JF; Ueno R
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
    Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of constipation in Parkinson's disease.
    Rossi M; Merello M; Perez-Lloret S
    Expert Opin Pharmacother; 2015 Mar; 16(4):547-57. PubMed ID: 25539892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lubiprostone: a chloride channel activator.
    Lacy BE; Levy LC
    J Clin Gastroenterol; 2007 Apr; 41(4):345-51. PubMed ID: 17413599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lubiprostone in pediatric functional constipation.
    Faure C
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):275-7. PubMed ID: 24345830
    [No Abstract]   [Full Text] [Related]  

  • 19. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
    Vazquez Roque M; Camilleri M
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lubiprostone for the treatment of functional constipation in children.
    Hyman PE; Di Lorenzo C; Prestridge LL; Youssef NN; Ueno R
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):283-91. PubMed ID: 24048162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.